MILAN—The investigational agent degarelix provides more rapid and profound testosterone suppression than conventional androgen deprivation therapy in men with advanced prostate cancer, researchers reported. Degarelix is a new synthetic peptide gonadotropin-releasing hormone (GnRH) blocker.
Adequate calorie intake, combined with a protein-restricted diet, can slow CKD progression.
MILAN—Intravesical alkalized lidocaine (PSD597) may be an effective short-term and possibly long-term treatment for patients with interstitial cystitis/painful bladder syndrome (IC/PBS), data suggest.
In 2007, an international panel convened by the American Urological Association (AUA) and the European Association of Urology (EAU) updated the AUA ureteral stone guidelines.
WASHINGTON, D.C.—Percutaneous declotting of hemodialysis grafts less than 30 days from initial placement may result in shorter secondary patency compared with declotting of older grafts, according to researchers.
Infections are a serious complication and leading cause of death in debilitated patients, including those with cancer, immunosuppression (e.g., transplantation or AIDS patients), diabetes, chronic renal failure, severe neurologic conditions such as Parkinsonism or spinal cord injury, and the elderly.
Two Illinois juries recently awarded huge verdicts to injured patients in unrelated malpractice cases.
Older individuals suffering from complications of type 2 diabetes are at increased risk of falling, researchers found.
A Charleston, W. Va., surgeon recently won a $25 million judgment in a defamation lawsuit against a local hospital.
Doctors, lawyers, and administrators at a suburban Philadelphia hospital are collaborating on a mediation program they hope will keep many malpractice cases out of court.
